Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/269724
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara |
Autor: | Jiménez de Oya, Nereida; Pérez, Patricia; Blázquez, Ana B.; Escribano-Romero, Estela; Esteban, Mariano CSIC ORCID ; Saiz Calahorra, Juan Carlos; García-Arriaza, Juan CSIC ORCID ; Martín-Acebes, M. A. | Palabras clave: | Zika virus MVA Imunogenicity; vaccine; vaccine safety C antibody-dependent enhancement of infection Cross-protection West Nile virus Vaccine vaccine safety |
Fecha de publicación: | 15-mar-2022 | Editor: | Multidisciplinary Digital Publishing Institute | Citación: | Pharmaceuticals 15(3); 354 (2022) | Resumen: | Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain-Barré syndrome, which is an autoimmune disease with neurological symptoms. The recent description of the first local infections of ZIKV in the European continent together with the expansion of one of its potential vectors, the Asian tiger mosquito (Aedes albopictus), invite us to be prepared for future outbreaks of ZIKV in this geographical region. However, the antigenic similarities of ZIKV with other flaviviruses can lead to an immune cross-reactivity with other circulating flaviviruses inducing, in some cases, flavivirus-disease exacerbation by antibody-dependent enhancement (ADE) of infection, which is a major concern for ZIKV vaccine development. Until now, West Nile virus (WNV) is the main medically relevant flavivirus circulating in the Mediterranean Basin. Therefore, anticipating the potential scenario of emergency vaccination against ZIKV in areas of Europe where WNV is endemic, in this investigation, we have evaluated the cross-reactivity between WNV and our previously developed ZIKV vaccine candidate based on modified vaccinia virus Ankara (MVA) vector expressing ZIKV structural proteins (MVA-ZIKV). To this end, mice were first immunized with MVA-ZIKV, subsequently challenged with WNV, and then, the ZIKV- and WNV-specific immune responses and protection against WNV were evaluated. Our results indicate low cross-reactivity between the MVA-ZIKV vaccine candidate and WNV and absence of ADE, supporting the safety of this ZIKV vaccine candidate in areas where the circulation of WNV is endemic. | Descripción: | 8 Pag.. | Versión del editor: | https://doi.org/10.3390/ph15030354 | URI: | http://hdl.handle.net/10261/269724 | DOI: | 10.3390/ph15030354 | ISSN: | 1424-8247 |
Aparece en las colecciones: | (CNB) Artículos (INIA) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
Low-Immune-Cross-Reactivity-between.pdf | artículo | 848,21 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
2
checked on 23-abr-2024
SCOPUSTM
Citations
2
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
2
checked on 26-feb-2024
Page view(s)
67
checked on 22-abr-2024
Download(s)
56
checked on 22-abr-2024